🦊/Companies

BlossomHill Therapeutics

San Diego, US · Founded 2020 · Delaware corporation · 1 known investors

Find your way into BlossomHill Therapeutics

350 people in our graph share verified history with the BlossomHill Therapeutics team — schools, employers, funds. One of them is your warm intro.

Anthony Linunlockedknows YISHAN LI · together at University of California, Berkeley (overlapped)
×9knows the team · via University of California, Berkeley
knows the team · via University of California, Berkeley, Haas School of Business
knows the team · via University of Science and Technology of China

Founders & leadership

BlossomHill Therapeutics was founded in 2020 by Jingrong Jean Cui.

JJJingrong Jean Cui
Jingrong Jean CuiFounder
YLYISHAN LI
YISHAN LIinExecutiveYishan Li holds a Ph.D. in biochemistry from Ohio State University and an M.B.A. from UC Berkeley's Haas School of Business; he co-founded Turning Point Therapeutics (acquired by Bristol Myers Squibb for $4.1 billion in 2022) where he served as Chairman and CEO, and later co-founded BlossomHill Therapeutics, a small molecule drug discovery company focused on oncology and autoimmune disorders that completed an IPO on NASDAQ in 2026.
LP
Li Peter YishanNamed on SEC filing

Board

GL
GEORGE LEEBoard director
CG
CARL GORDONBoard director
SA
SUNDEEP AGRAWALBoard director
BC
BIHUA CHENBoard director
TS
TIMOTHY STUBBSBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$245.8M disclosed across 4 rounds · 2020–2025

$84.2MraisedDec 2025 · 47 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • GEORGE LEEDirector
  • CARL GORDONDirector
  • YISHAN LIExecutive Officer, Director
  • SUNDEEP AGRAWALDirector
  • BIHUA CHENDirector
  • TIMOTHY STUBBSDirector
  • JINGRONG JEAN CUIExecutive Officer, Director
Offering amount
$84.2M
Amount sold
$84.2M
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$88.6MraisedJan 2024 · 44 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Sundeep AgrawalDirector
  • Jingrong Jean CuiExecutive Officer, Director
  • Bihua ChenDirector
  • George LeeDirector
  • Carl GordonDirector
  • Yishan LiExecutive Officer, Director
  • Hongbo LuDirector
Offering amount
$100M
Amount sold
$88.6M
First sale
Dec 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$71MraisedMar 2021 · 27 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • George LeeDirector
  • Li Peter YishanExecutive Officer, Director
  • Bihua ChenDirector
  • Carl GordonDirector
  • Jingrong Jean CuiExecutive Officer, Director
Offering amount
$71M
Amount sold
$71M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$2MraisedJan 2021 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jingrong Jean CuiExecutive Officer, Director
  • Li Peter YishanExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Frequently asked questions

Who founded BlossomHill Therapeutics?
BlossomHill Therapeutics was founded by Jingrong Jean Cui in 2020.
Who are BlossomHill Therapeutics's investors?
BlossomHill Therapeutics's investors include Lilly Asia Ventures.
How much funding has BlossomHill Therapeutics raised?
BlossomHill Therapeutics has disclosed $245.8M raised across 4 rounds.
Where is BlossomHill Therapeutics headquartered?
BlossomHill Therapeutics is headquartered in San Diego, US.